Assembly BiosciencesASMB -3.27%31 Earnings Yield (Joel Greenblatt) % is -6.25% as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,336 Biotechnology companies, Assembly Biosciences ranks better than 65.19% on this metric.
Assembly Biosciences's Enterprise Value for the quarter that ended in Mar. 2026 was $216.89 Mil.
Assembly Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-13.55 Mil. Assembly Biosciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -6.25%.
The historical rank and industry rank for Assembly Biosciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ASMB'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4154.13 Med: -6.43 Max: 2239.78
Current: -4.18
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Assembly Biosciences was 2239.78%. The lowest was -4154.13%. And the median was -6.43%.
ASMB's Earnings Yield (Joel Greenblatt) % is ranked better than 65.19% of 1336
companies
in the Biotechnology industry
Industry Median: -9.745
vs ASMB: -4.18
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Assembly Biosciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Assembly Biosciences Earnings Yield (Joel Greenblatt) % Related Terms
Assembly Biosciences Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Assembly Biosciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Assembly Biosciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Assembly Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.55 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -6.25% mean?
Assembly Biosciences (ASMB) has a Earnings Yield (Joel Greenblatt) % of -6.25% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #465 out of 1336 companies in the Biotechnology industry, placing it in the top 34.8%.
Is Assembly Biosciences' Earnings Yield (Joel Greenblatt) % too high?
Assembly Biosciences' current Earnings Yield (Joel Greenblatt) % is -6.25%. Based on the distribution chart, Assembly Biosciences ranks #465 out of 1336 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Earnings Yield (Joel Greenblatt) % compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #465 out of 1336 companies for Earnings Yield (Joel Greenblatt) %. This puts Assembly Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Earnings Yield (Joel Greenblatt) % is -6.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Earnings Yield (Joel Greenblatt) % of -6.25%. The current Earnings Yield (Joel Greenblatt) % is -6.25%. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Earnings Yield (Joel Greenblatt) % is -6.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score
Get the complete analysis for ASMB
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
